2. Academic Validation
  3. Discovery of INCB9471, a Potent, Selective, and Orally Bioavailable CCR5 Antagonist with Potent Anti-HIV-1 Activity

Discovery of INCB9471, a Potent, Selective, and Orally Bioavailable CCR5 Antagonist with Potent Anti-HIV-1 Activity

  • ACS Med Chem Lett. 2010 Aug 25;1(9):483-7. doi: 10.1021/ml1001536.
Chu-Biao Xue 1,  Lihua Chen 1,  Ganfeng Cao 1,  Ke Zhang 1,  Anlai Wang 1,  David Meloni 1,  Joseph Glenn 1,  Rajan Anand 1,  Michael Xia 1,  Ling Kong 1,  Taisheng Huang 1,  Hao Feng 1,  Changsheng Zheng 1,  Mei Li 1,  Laurine Galya 1,  Jiacheng Zhou 1,  Niu Shin 1,  Fredric Baribaud 1,  Kim Solomon 1,  Peggy Scherle 1,  Bitao Zhao 1,  Sharon Diamond 1,  Tom Emm 1,  Douglas Keller 1,  Nancy Contel 1,  Swamy Yeleswaram 1,  Kris Vaddi 1,  Gregory Hollis 1,  Robert Newton 1,  Steven Friedman 1,  Brian Metcalf 1
Affiliations

Affiliation

  • 1 Incyte Corporation, Experimental Station E336, Wilmington, Delaware 19880.
PMID: 24900235 DOI: 10.1021/ml1001536
Abstract

To identify a CCR5 Antagonist as an HIV-1 entry inhibitor, we designed a novel series of indane derivatives based on conformational considerations. Modification on the indane ring led to the discovery of compound 22a (INCB9471) that exhibited high affinity for CCR5, potent anti-HIV-1 activity, high receptor selectivity, excellent oral bioavailability, and a tolerated safety profile. INCB9471 has entered human clinical trials.

Keywords

CCR5; HIV-1; antagonist; antiviral; coreceptor.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z